Virginia Kimonis, MD
Enriched profileProfessor, Division of Genetics and Metabolism, Department of Pediatrics · UC Irvine School of Medicine
Virginia Kimonis is Professor, Division of Genetics and Metabolism, Department of Pediatrics at UC Irvine School of Medicine. OpenAlex indexes 341 publications with 15,999 citations (h-index 60); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 11 Oct 2026
Overview
Updated 14 Oct 2026
Virginia Kimonis, MD, is Professor, Division of Genetics and Metabolism, Department of Pediatrics at UC Irvine School of Medicine / UCI Health. The public record shows 341 publications with 15,999 citations (h-index 60), centered on Genetic Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis Research, Lysosomal Storage Disorders Research. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 5 companies, 11 NIH-funded awards (2007–2026).
- Most recent indexed publication: 2026 · American journal of medical genetics. Part A
- Top research focus: Genetic Neurodegenerative Diseases
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 41 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 177.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.
Sponsor: University of California, Irvine
- Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
Sponsor: University of California, Irvine
Industry payments
Updated 14 Oct 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20256 payments
- Chiesi USA, Inc.Program year20256 payments
- Soleno Therapeutics, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
77.5%Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme55%Fabrazyme100%Part D<11 patientsHydrolytic Lysosomal Glycogen-specific Enzyme22.5%Lumizyme100%Part D<11 patientsBlood & clotting
22.5%Salt solutions22.5%Sodium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
11 NIH research awards on record, funded 2007–2026 per NIH RePORTER. The latest:
- Correction of VCP Disease Pathology with Antisense Oligonucleotides
University of California-Irvine
FY2026$431,750R21AG093390 - GYS1 Oligonucleotide Treatment as a Substrate Inhibitor for Pompe disease
University of California-Irvine
FY2026$431,750R21HD122115 - Epigenetic Silencing of VCP via an ASO-Conjugate Based Induced Proximity System for the Treatment of FTD-ALS in VCP Disease
Junipero Therapeutics, Inc.
FY2026$306,872R41NS150094
Congress activity
Updated 14 Oct 2026
2 congress contributions (2012–2024) across AACR, ENDO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Severe Phenotype in an Indian Family With Progressive Pseudorheumatoid Arthropathy of Childhood.
American journal of medical genetics. Part A
Case Report2026 - Influence of Molecular Genetic Classes on Behavior in Prader-Willi Syndrome.
American journal of medical genetics. Part B, Neuropsychiatric genetics
Article2026 - Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study.
The Journal of clinical endocrinology and metabolism
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALSArticle1,485 citations2013
- 02
- 03Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndromeArticle962 citations1997
- 04Nutritional phases in Prader–Willi syndromeArticle447 citations2011
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cureduchenne.org ↗
- Board certified
Clinical Genetics and Genomics, American Board of Medical Genetics and Genomics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
Awards & honors
honors on the public record- Physician of Excellence
Orange County Medical Association
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cannabis.uci.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cureduchenne.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Cameron Carter, MD
UC Irvine School of Medicine
Ronald Wapner, MD
Columbia University Irving Medical Center
Robert Hopkin, MD
Cincinnati Children's Hospital Medical Center
Nicola Longo, MD
University of California, Los Angeles
Joel Charrow, MD
Northwestern University